Pro Medicus (PMCUF) Stock Price, News & Analysis

Company Overview

Pro Medicus Limited is an Australia‐based healthcare technology company specializing in advanced medical imaging IT solutions. Its core offerings include radiology information systems (RIS), picture archiving and communication systems (PACS), and enterprise imaging platforms designed to streamline diagnostic workflows and enhance image management for healthcare providers.

The company’s flagship product suite, Visage 7, delivers high-performance visualization and reporting capabilities, enabling radiologists to access and manipulate large datasets with minimal latency. Pro Medicus also provides complementary modules for artificial intelligence integration, data analytics, and teleradiology, supporting both on-premises and cloud-based deployment models.

Founded in 1983 and headquartered in Melbourne, Pro Medicus has expanded its footprint to serve hospitals, imaging centers, and academic medical institutions across Australia, Europe, and North America. Key installations include major health systems and specialist clinics that rely on Pro Medicus solutions to manage high-volume imaging workloads and to collaborate seamlessly across multidisciplinary care teams.

Over its history, Pro Medicus has built a reputation for rapid image delivery and scalable architecture, earning partnerships with leading medical research centers and device vendors. The company is led by an experienced executive team with deep expertise in medical imaging, software engineering, and healthcare operations, driving its mission to improve patient outcomes through innovative information technology.

Key Stats

• Today's Range: $180.79 to $180.79
• 50-Day Range: $183.43 to $210.25
• 52-Week Range: $100.45 to $218.25
• Volume: 5 shs
• Average Volume: 647 shs
• Market Capitalization: N/A
• P/E Ratio: 12,052.67
• Dividend Yield: 0.01%
• Price Target: N/A
• Consensus Rating: N/A

Pro Medicus Stock Analysis - MarketRank™

Pro Medicus scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Pro Medicus.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pro Medicus is 12,052.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 233.17.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pro Medicus is 12,052.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 84.98.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Pro Medicus has a short interest ratio ("days to cover") of 2157, which indicates bearish sentiment.

Change versus previous month

Short interest in Pro Medicus has recently increased by 6.01%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Pro Medicus pays a meaningful dividend of 1.63%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Pro Medicus does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Pro Medicus is 133.33%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Pro Medicus has a short interest ratio ("days to cover") of 2157, which indicates bearish sentiment.

Change versus previous month

Short interest in Pro Medicus has recently increased by 6.01%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.37

News Sentiment

Pro Medicus has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Pro Medicus this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pro Medicus insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 10.84% of the stock of Pro Medicus is held by institutions.

PMCUF Stock Analysis - Frequently Asked Questions

How have PMCUF shares performed this year?

Pro Medicus' stock was trading at $155.27 at the beginning of 2025. Since then, PMCUF shares have increased by 16.4% and is now trading at $180.79.

How do I buy shares of Pro Medicus?

Shares of PMCUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PMCUF
• CIK: 2013003
• Web: www.promed.com.au
• Phone: 61 3 9429 8800
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 12,052.67
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A